The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28306255 |
89 |
Development of Potent and Selective Antagonists for the UTP-Activated P2Y |
University of Bonn |
| 26447940 |
27 |
Identification of Highly Promising Antioxidants/Neuroprotectants Based on Nucleoside 5'-Phosphorothioate Scaffold. Synthesis, Activity, and Mechanisms of Action. |
Bar-Ilan University |
| 24931384 |
66 |
Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents. |
Bristol-Myers Squibb Research |
| 24846781 |
14 |
Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(a or¿)-thio-(a,ß- orß,¿)-methylenetriphosphate scaffold. |
Bar-Ilan University |
| 24513044 |
19 |
Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent. |
Bristol-Myers Squibb |
| 24767843 |
40 |
2-Amino-1,3,4-thiadiazoles in the 7-hydroxy-N-neopentyl spiropiperidine indolinyl series as potent P2Y1 receptor antagonists. |
Bristol-Myers Squibb |
| 24164581 |
82 |
Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist. |
Bristol-Myers Squibb |
| 24269480 |
22 |
Potent P2Y1 urea antagonists bearing various cyclic amine scaffolds. |
Bristol-Myers Squibb |
| 23769642 |
20 |
Design, synthesis and structure-activity relationships of zwitterionic spirocyclic compounds as potent CCR1 antagonists. |
Astrazeneca |
| 23743287 |
21 |
2-Aminothiazole based P2Y(1) antagonists as novel antiplatelet agents. |
Bristol-Myers Squibb |
| 23668989 |
28 |
New azole antagonists with high affinity for the P2Y(1) receptor. |
Bristol-Myers Squibb |
| 23751098 |
24 |
Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists. |
Bar-Ilan University |
| 23602442 |
28 |
Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility. |
Bristol-Myers Squibb |
| 23368907 |
62 |
Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists. |
Bristol-Myers Squibb Research and Development |
| 16250663 |
8 |
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. |
University of Bonn |
| 22984835 |
66 |
Identification of high-affinity P2Y12 antagonists based on a phenylpyrazole glutamic acid piperazine backbone. |
Sanofi-Aventis Deutschland |
| 22831801 |
8 |
Virtual screening leads to the discovery of novel non-nucleotide P2Y1 receptor antagonists. |
National Institutes of Health |
| 20542694 |
20 |
Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists. |
Glaxosmithkline |
| 18445527 |
46 |
P2Y1 receptor antagonists as novel antithrombotic agents. |
Pfizer |
| 18232657 |
67 |
Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor. |
Inspire Pharmaceuticals |
| 17079144 |
19 |
Novel nucleotide triphosphates as potent P2Y2 agonists with enhanced stability over UTP. |
Ucb-Group |
| 17011188 |
45 |
Novel nucleotide triphosphates as potent P2Y2 agonists. |
Ucb-Group |
| 16539385 |
11 |
Diadenosine and diuridine poly(borano)phosphate analogues: synthesis, chemical and enzymatic stability, and activity at P2Y1 and P2Y2 receptors. |
Bar-Ilan University |
| 15481977 |
62 |
Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. |
National Institute of Diabetes and Digestive and Kidney Diseases |
| 11831909 |
4 |
Novel antagonists acting at the P2Y(1) purinergic receptor: synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques. |
Universit£ |
| 12213051 |
207 |
Purine and pyrimidine (P2) receptors as drug targets. |
National Institute of Diabetes |
| 11985476 |
35 |
Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists. |
National Institute of Diabetes |
| 11754592 |
21 |
Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. |
National Institute of Diabetes |
| 9554879 |
26 |
Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. |
National Institute of Diabetes |
| 21090681 |
18 |
Diadenosine 5',5''-(boranated)polyphosphonate analogues as selective nucleotide pyrophosphatase/phosphodiesterase inhibitors. |
Bar-Ilan University |
| 20394377 |
12 |
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. |
University of Pavia |
| 20192270 |
3 |
Structure-activity relationship of (N)-Methanocarba phosphonate analogues of 5'-AMP as cardioprotective agents acting through a cardiac P2X receptor. |
National Institutes of Diabetes and Digestive and Kidney Diseases |
| 20175517 |
8 |
A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold. |
Bar-Ilan University |
| 18926700 |
35 |
Tetrahydro-4-quinolinamines identified as novel P2Y(1) receptor antagonists. |
Glaxosmithkline |
| 17564423 |
24 |
P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring. |
National Institute of Diabetes and Digestive and Kidney Diseases |
| 17524641 |
69 |
3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists. |
Glaxosmithkline |
| 14584948 |
26 |
2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. |
Niddk |
| 27331270 |
54 |
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists. |
National Institute of Diabetes and Digestive and Kidney Diseases |
| 26588064 |
34 |
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. |
Glsynthesis |
| 17941622 |
5 |
New iantherans from the marine sponge Ianthella quadrangulata: novel agonists of the P2Y(11) receptor. |
University of Bonn |
| 30223118 |
12 |
Design, synthesis, and biological evaluation of 2-(phenoxyaryl)-3-urea derivatives as novel P2Y |
University of Chinese Academy of Sciences |
| 29254895 |
31 |
Current knowledge on the nucleotide agonists for the P2Y2 receptor. |
China Pharmaceutical University |
| 29852070 |
101 |
Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-? Inhibitors. |
Pharmaron-Beijing |
| 26833890 |
18 |
Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease. |
Yogi Vemana University |
| 26469307 |
7 |
Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b. |
University of Leipzig |
| 7678654 |
30 |
Synthesis and evaluation of 2-pyridinone derivatives as specific HIV-1 reverse transcriptase inhibitors. 3. Pyridyl and phenyl analogs of 3-aminopyridin-2(1H)-one. |
Merck Research Laboratories |
Search and Browse
